ALKERMES (ALKS) — insider trading
Health Care · NASDAQ
ALKERMES (ALKS) has 87 reported SEC Form 4 insider transactions in our data, including 18 open-market sales among the most recent 87 (latest 2026-10-02).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | Gaffin David Joseph | Officer (EVP, CLO, Alkermes, Inc.) | Open-market sale | 2,034 | $41.03 | $83.5K | Form 4 |
| 2026-09-03 | Gaffin David Joseph | Officer (EVP, CLO, Alkermes, Inc.) | Open-market sale | 2,034 | $48.01 | $97.7K | Form 4 |
| 2026-09-01 | Hopkinson Craig C. | Officer (EVP R&D, Chief Medical Officer) | Option exercise / conversion (derivative) | 5,000 | — | $0 | Form 4 |
| 2026-09-01 | Hopkinson Craig C. | Officer (EVP R&D, Chief Medical Officer) | Open-market sale | 9,000 | $46.99 | $422.9K | Form 4 |
| 2026-09-01 | Hopkinson Craig C. | Officer (EVP R&D, Chief Medical Officer) | Option exercise / conversion | 5,000 | $24.59 | $123.0K | Form 4 |
| 2026-08-17 | Nichols Christian Todd | Officer (SVP, Chief Commercial Officer) | Open-market sale | 664 | $49.65 | $33.0K | Form 4 |
| 2026-08-17 | Nichols Christian Todd | Officer (SVP, Chief Commercial Officer) | Open-market sale | 6,912 | $49.19 | $340.0K | Form 4 |
| 2026-08-05 | Jackson Blair Curtis | Director, Officer (President & CEO, Alkermes plc) | Grant / award / vesting (derivative) | 124,305 | — | $0 | Form 4 |
| 2026-08-05 | Jackson Blair Curtis | Director, Officer (President & CEO, Alkermes plc) | Grant / award / vesting (derivative) | 93,229 | — | $0 | Form 4 |
| 2026-08-03 | Gaffin David Joseph | Officer (EVP, CLO, Alkermes, Inc.) | Open-market sale | 2,034 | $48.58 | $98.8K | Form 4 |
| 2026-08-03 | Hopkinson Craig C. | Officer (EVP R&D, Chief Medical Officer) | Option exercise / conversion (derivative) | 4,896 | — | $0 | Form 4 |
| 2026-08-03 | Hopkinson Craig C. | Officer (EVP R&D, Chief Medical Officer) | Option exercise / conversion (derivative) | 104 | — | $0 | Form 4 |
| 2026-08-03 | Hopkinson Craig C. | Officer (EVP R&D, Chief Medical Officer) | Open-market sale | 9,000 | $48.58 | $437.2K | Form 4 |
| 2026-08-03 | Hopkinson Craig C. | Officer (EVP R&D, Chief Medical Officer) | Option exercise / conversion | 4,896 | $24.59 | $120.4K | Form 4 |
| 2026-08-03 | Hopkinson Craig C. | Officer (EVP R&D, Chief Medical Officer) | Option exercise / conversion | 104 | $19.34 | $2.0K | Form 4 |
| 2026-08-03 | snyderman nancy lynn MD | Director | Option exercise / conversion (derivative) | 16,524 | — | $0 | Form 4 |
| 2026-08-03 | snyderman nancy lynn MD | Director | Option exercise / conversion (derivative) | 27,948 | — | $0 | Form 4 |
| 2026-08-03 | snyderman nancy lynn MD | Director | Open-market sale | 44,472 | $50.35 | $2.24M | Form 4 |
| 2026-08-03 | snyderman nancy lynn MD | Director | Option exercise / conversion | 16,524 | $46.72 | $772.0K | Form 4 |
| 2026-08-03 | snyderman nancy lynn MD | Director | Option exercise / conversion | 27,948 | $46.72 | $1.31M | Form 4 |
| 2026-07-06 | Gaffin David Joseph | Officer (EVP, CLO, Alkermes, Inc.) | Open-market sale | 2,034 | $54.03 | $109.9K | Form 4 |
| 2026-07-01 | Hopkinson Craig C. | Officer (EVP R&D, Chief Medical Officer) | Option exercise / conversion (derivative) | 5,000 | — | $0 | Form 4 |
| 2026-07-01 | Hopkinson Craig C. | Officer (EVP R&D, Chief Medical Officer) | Open-market sale | 700 | $52.13 | $36.5K | Form 4 |
| 2026-07-01 | Hopkinson Craig C. | Officer (EVP R&D, Chief Medical Officer) | Open-market sale | 8,300 | $51.46 | $427.1K | Form 4 |
| 2026-07-01 | Hopkinson Craig C. | Officer (EVP R&D, Chief Medical Officer) | Option exercise / conversion | 5,000 | $19.34 | $96.7K | Form 4 |
| 2026-06-12 | Wright Christopher I | Director | Open-market sale | 2,000 | $45.10 | $90.2K | Form 4 |
| 2026-06-04 | Gaffin David Joseph | Officer (EVP, CLO, Alkermes, Inc.) | Open-market sale | 2,034 | $43.05 | $87.6K | Form 4 |
| 2026-06-01 | Hopkinson Craig C. | Officer (EVP R&D, Chief Medical Officer) | Option exercise / conversion (derivative) | 5,000 | — | $0 | Form 4 |
| 2026-06-01 | Hopkinson Craig C. | Officer (EVP R&D, Chief Medical Officer) | Open-market sale | 9,000 | $41.67 | $375.0K | Form 4 |
| 2026-06-01 | Hopkinson Craig C. | Officer (EVP R&D, Chief Medical Officer) | Option exercise / conversion | 5,000 | $19.34 | $96.7K | Form 4 |
| 2026-05-29 | Parisi Samuel Joseph | Officer (VP, Finance (Interim PAO)) | Option exercise / conversion (derivative) | 12,825 | — | $0 | Form 4 |
| 2026-05-29 | Parisi Samuel Joseph | Officer (VP, Finance (Interim PAO)) | Option exercise / conversion (derivative) | 3,392 | — | $0 | Form 4 |
| 2026-05-29 | Parisi Samuel Joseph | Officer (VP, Finance (Interim PAO)) | Open-market sale | 16,217 | $42.36 | $687.0K | Form 4 |
| 2026-05-29 | Parisi Samuel Joseph | Officer (VP, Finance (Interim PAO)) | Option exercise / conversion | 12,825 | $19.34 | $248.0K | Form 4 |
| 2026-05-29 | Parisi Samuel Joseph | Officer (VP, Finance (Interim PAO)) | Option exercise / conversion | 3,392 | $20.03 | $67.9K | Form 4 |
| 2026-05-21 | Cooke Shane | Director | Option exercise / conversion (derivative) | 6,142 | — | — | Form 4 |
| 2026-05-21 | Cooke Shane | Director | Shares withheld for taxes / exercise cost | 3,207 | $36.95 | $118.5K | Form 4 |
| 2026-05-21 | Cooke Shane | Director | Option exercise / conversion | 6,142 | — | — | Form 4 |
| 2026-05-21 | GAYNOR RICHARD | Director | Option exercise / conversion (derivative) | 6,142 | — | — | Form 4 |
| 2026-05-21 | GAYNOR RICHARD | Director | Shares withheld for taxes / exercise cost | 1,475 | $36.95 | $54.5K | Form 4 |
| 2026-05-21 | GAYNOR RICHARD | Director | Option exercise / conversion | 6,142 | — | — | Form 4 |
| 2026-05-21 | LAURENCIN CATO T | Director | Option exercise / conversion (derivative) | 6,142 | — | — | Form 4 |
| 2026-05-21 | LAURENCIN CATO T | Director | Shares withheld for taxes / exercise cost | 1,475 | $36.95 | $54.5K | Form 4 |
| 2026-05-21 | LAURENCIN CATO T | Director | Option exercise / conversion | 6,142 | — | — | Form 4 |
| 2026-05-21 | Lurker Nancy | Director | Option exercise / conversion (derivative) | 6,142 | — | — | Form 4 |
| 2026-05-21 | Lurker Nancy | Director | Shares withheld for taxes / exercise cost | 1,475 | $36.95 | $54.5K | Form 4 |
| 2026-05-21 | Lurker Nancy | Director | Option exercise / conversion | 6,142 | — | — | Form 4 |
| 2026-05-21 | MCKEON BRIAN P | Director | Option exercise / conversion (derivative) | 6,142 | — | — | Form 4 |
| 2026-05-21 | MCKEON BRIAN P | Director | Shares withheld for taxes / exercise cost | 1,475 | $36.95 | $54.5K | Form 4 |
| 2026-05-21 | MCKEON BRIAN P | Director | Option exercise / conversion | 6,142 | — | — | Form 4 |
| 2026-05-21 | snyderman nancy lynn MD | Director | Option exercise / conversion (derivative) | 6,142 | — | — | Form 4 |
| 2026-05-21 | snyderman nancy lynn MD | Director | Shares withheld for taxes / exercise cost | 1,475 | $36.95 | $54.5K | Form 4 |
| 2026-05-21 | snyderman nancy lynn MD | Director | Option exercise / conversion | 6,142 | — | — | Form 4 |
| 2026-05-21 | Wilson Frank Anders | Director | Option exercise / conversion (derivative) | 6,142 | — | — | Form 4 |
| 2026-05-21 | Wilson Frank Anders | Director | Shares withheld for taxes / exercise cost | 1,475 | $36.95 | $54.5K | Form 4 |
| 2026-05-21 | Wilson Frank Anders | Director | Option exercise / conversion | 6,142 | — | — | Form 4 |
| 2026-05-21 | Wright Christopher I | Director | Option exercise / conversion (derivative) | 6,142 | — | — | Form 4 |
| 2026-05-21 | Wright Christopher I | Director | Shares withheld for taxes / exercise cost | 1,475 | $36.95 | $54.5K | Form 4 |
| 2026-05-21 | Wright Christopher I | Director | Option exercise / conversion | 6,142 | — | — | Form 4 |
| 2026-05-20 | Cooke Shane | Director | Grant / award / vesting (derivative) | 5,409 | — | $0 | Form 4 |
| 2026-05-20 | Cooke Shane | Director | Grant / award / vesting (derivative) | 11,538 | — | $0 | Form 4 |
| 2026-05-20 | GAYNOR RICHARD | Director | Grant / award / vesting (derivative) | 5,409 | — | $0 | Form 4 |
| 2026-05-20 | GAYNOR RICHARD | Director | Grant / award / vesting (derivative) | 11,538 | — | $0 | Form 4 |
| 2026-05-20 | Cooke Shane | Director | Grant / award / vesting (derivative) | 5,409 | — | $0 | Form 4/A |
| 2026-05-20 | Cooke Shane | Director | Grant / award / vesting (derivative) | 11,538 | — | $0 | Form 4/A |
| 2026-05-20 | GAYNOR RICHARD | Director | Grant / award / vesting (derivative) | 5,409 | — | $0 | Form 4/A |
| 2026-05-20 | GAYNOR RICHARD | Director | Grant / award / vesting (derivative) | 11,538 | — | $0 | Form 4/A |
| 2026-05-20 | LAURENCIN CATO T | Director | Grant / award / vesting (derivative) | 5,409 | — | $0 | Form 4 |
| 2026-05-20 | LAURENCIN CATO T | Director | Grant / award / vesting (derivative) | 11,538 | — | $0 | Form 4 |
| 2026-05-20 | Lurker Nancy | Director | Grant / award / vesting (derivative) | 5,409 | — | $0 | Form 4 |
| 2026-05-20 | Lurker Nancy | Director | Grant / award / vesting (derivative) | 11,538 | — | $0 | Form 4 |
| 2026-05-20 | MCKEON BRIAN P | Director | Grant / award / vesting (derivative) | 5,409 | — | $0 | Form 4 |
| 2026-05-20 | MCKEON BRIAN P | Director | Grant / award / vesting (derivative) | 11,538 | — | $0 | Form 4 |
| 2026-05-20 | snyderman nancy lynn MD | Director | Grant / award / vesting (derivative) | 5,409 | — | $0 | Form 4 |
| 2026-05-20 | snyderman nancy lynn MD | Director | Grant / award / vesting (derivative) | 11,538 | — | $0 | Form 4 |
| 2026-05-20 | Wilson Frank Anders | Director | Grant / award / vesting (derivative) | 5,409 | — | $0 | Form 4 |
| 2026-05-20 | Wilson Frank Anders | Director | Grant / award / vesting (derivative) | 11,538 | — | $0 | Form 4 |
| 2026-05-20 | Wright Christopher I | Director | Grant / award / vesting (derivative) | 5,409 | — | $0 | Form 4 |
| 2026-05-20 | Wright Christopher I | Director | Grant / award / vesting (derivative) | 11,538 | — | $0 | Form 4 |
| 2026-05-04 | Gaffin David Joseph | Officer (EVP, CLO, Alkermes, Inc.) | Open-market sale | 2,034 | $33.20 | $67.5K | Form 4 |
| 2026-05-01 | Hopkinson Craig C. | Officer (EVP R&D, Chief Medical Officer) | Option exercise / conversion (derivative) | 5,000 | — | $0 | Form 4 |
| 2026-05-01 | Hopkinson Craig C. | Officer (EVP R&D, Chief Medical Officer) | Open-market sale | 9,000 | $33.40 | $300.6K | Form 4 |
| 2026-05-01 | Hopkinson Craig C. | Officer (EVP R&D, Chief Medical Officer) | Option exercise / conversion | 5,000 | $19.34 | $96.7K | Form 4 |
| 2026-04-11 | Lurker Nancy | Director | Option exercise / conversion (derivative) | 3,751 | — | — | Form 4 |
| 2026-04-11 | Lurker Nancy | Director | Shares withheld for taxes / exercise cost | 901 | $33.36 | $30.1K | Form 4 |
| 2026-04-11 | Lurker Nancy | Director | Option exercise / conversion | 3,751 | — | — | Form 4 |
| 2026-04-06 | Gaffin David Joseph | Officer (EVP, CLO, Alkermes, Inc.) | Open-market sale | 2,034 | $34.57 | $70.3K | Form 4 |
Ask the chat about ALKS's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: ALKERMES (ALKS).
Last updated 2026-10-02 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.